Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus

Stopped early · Phase 1

Conditions studied: Type 2 Diabetes Mellitus

In brief

This is a phase 1 multiple ascending dose (MAD) study, conducted in subjects with Type 2 Diabetes Mellitus.

Key facts

Study ID

NCT03332836

Run by

Hanmi Pharmaceutical Company Limited

People needed

21

Starts

2017-10-25

Expected to finish

2020-09-30

Last updated by the study team

2021-04-01

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Type 2 diabetes mellitus
• Female subjects must be non-pregnant and non-lactating

You may not qualify if…

• Recurrent severe hypoglycemia or hypoglycemic unawareness or recent severe ketoacidosis, as judged by the Investigator
• Pregnant or lactating women
• Participation in an investigational study within 30 days prior to dosing

Where it is running

• Hanmi Investigative Site — Chula Vista, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.